secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2024-08-29T23:59:59+00:00
Accession:  0001104659-24-094609
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in ARID1a-deficient ovarian cancers
--------------------------------------------------------------------------------

- FDA granted Orphan Drug Designation for NXP800 for treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
- CEO Ron Bentsur noted prevalence exceeds 200,000 threshold; designation for a disease subset is uncommon.
- Ongoing Phase 1b trial in platinum-resistant ARID1a-mutated ovarian cancer; data update expected fall 2024.
- Nuvectis Pharma (NVCT) stock trades on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924094609/0001104659-24-094609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924094609/tm2422951d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-094609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer